摘要
目的分析幽门螺杆菌感染患者在四联疗法根治的基础上联合益生菌的临床有效性。方法简单随机选择2022年2月—2024年2月福建医科大学附属泉州市第一医院收治的80例幽门螺杆菌感染患者为研究对象,根据不同的治疗方法分为两组,各40例。对照组给予四联疗法根治,观察组给予四联疗法根治联合益生菌治疗,比较两组炎症反应、胃肠激素水平、不良反应发生率。结果治疗2周后,观察组肿瘤坏死因子-α、超敏C反应蛋白水平低于对照组,差异有统计学意义(P均<0.05)。治疗2周后,观察组胃动素、胃泌素-17水平高于对照组,差异有统计学意义(P均<0.05)。观察组不良反应发生率为5.00%(2/40),低于对照组的22.50%(9/40),差异有统计学意义(χ^(2)=5.165,P<0.05)。结论幽门螺杆菌感染患者在四联疗法根治的基础上联合益生菌有利于改善炎症反应和胃肠激素水平,提高疗效,具有较高的临床应用价值。
Objective To analyze the clinical efficacy of probiotics combined with quadruple therapy in patients with Helicobacter pylori infection.Methods From February 2022 to February 2024,80 patients with Helicobacter pylori infection admitted to Quanzhou First Hospital Affiliated to Fujian Medical University were simple randomly selected as the research objects.According to different treatment methods,they were divided into two groups,40 cases in each group.The control group was treated with quadruple therapy,and the observation group was treated with quadruple therapy combined with probiotics.The inflammatory response,gastrointestinal hormones levels and incidence of adverse reactions were compared between the two groups.Results After 2 weeks of treatment,the levels of tumor necrosis factor-αand high-sensitivity C-reactive protein in the observation group were lower than those in the control group,and the differences were statistically significant(both P<0.05).After 2 weeks of treatment,the levels of motilin and gastrin-17 in the observation group were higher than those in the control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in the observation group was 5.00%(2/40),which was lower than 22.50%(9/40)in the control group,and the difference was statistically significant(χ^(2)=5.165,P<0.05).Conclusion The combination of probiotics on the basis of quadruple therapy in patients with Helicobacter pylori infection is beneficial to improve the inflammatory response and gastrointestinal hormones level,improve the curative effect,and has high clinical application value.
作者
许伯明
刘晓强
曾以琳
王育斌
XU Boming;LIU Xiaoqiang;ZENG Yilin;WANG Yubin(Department of Gastroenterology,Quanzhou First Hospital Affiliated to Fujian Medical University,Quanzhou,Fujian,362000,China)
出处
《中外医疗》
2024年第27期126-129,共4页
China & Foreign Medical Treatment
关键词
幽门螺杆菌感染
益生菌
炎症反应
四联疗法
胃肠激素
Helicobacter pylori infection
Probiotics
Inflammatory response
Quadruple therapy
Gastrointestinal hormone